RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT01175343 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

45

Enrollment

NIH

Sponsor class

Conditions

Recurrent Fallopian Tube Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Primary Peritoneal Carcinoma
Stage IV Fallopian Tube Cancer
Stage IV Ovarian Cancer
Stage IV Primary Peritoneal Cancer

Interventions

DRUG: Gamma-Secretase Inhibitor RO4929097
OTHER: Laboratory Biomarker Analysis

Sponsor

National Cancer Institute (NCI)